FSNANO

FS Nano is a clinical-stage biotechnology company based in Taiwan that specializes in the development of nanotechnology-based drug delivery systems. The company's core technology is a proprietary Nano-Micelle platform designed to improve the solubility, stability, and safety profiles of poorly water-soluble chemotherapeutic agents. By encapsulating active pharmaceutical ingredients like docetaxel and paclitaxel, FS Nano aims to reduce systemic toxicity and enhance therapeutic efficacy in various oncology indications. Their lead programs are currently undergoing clinical evaluation for the treatment of solid tumors, including breast and lung cancers. The company utilizes the 505(b)(2) regulatory pathway to accelerate the development of these bio-better formulations.